Video
Dr. Abi-Jaoudeh on Combination of Tirapazamine and Transarterial Embolization in HCC
Author(s):
Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).
Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).
In a dose-escalating study of the hypoxia-activating agent tirapazamine in combination with transarterial embolization, patients with intermediate-stage HCC were assigned to 1 of 5 cohorts according to dose.
Results showed that the combination was well tolerated. Additionally, there were no dose-limiting toxicities or serious adverse events reported.
The combination is moving toward a phase II study where it will be compared with chemoembolization, says Abi-Jaoudeh.
